Saw palmetto claim
This article was originally published in The Tan Sheet
Petition for rehearing en banc denied for supplement marketers seeking a health claim linking saw palmetto to benign prostatic hyperplasia. The petition was filed on behalf of the plaintiffs by Washington, D.C. law firm Emord & Associates Feb. 19 (1"The Tan Sheet" March 1, 2004, p. 15). Julian Whitaker, MD, the American Association for Health Freedom, Pure Encapsulations, Durk Pearson and Sandy Shaw plan to petition for a writ of certiorari to the Supreme Court before June 7...
You may also be interested in...
A group of supplement marketers seeking approval of a health claim linking saw palmetto to treatment of benign prostatic hyperplasia have filed a petition for an en banc rehearing with the U.S. Court of Appeals
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.